JN Biosciences LLC

February 8, 2021

A global phase 3 clinical study with a humanized anti-TIGIT IgG1 monoclonal antibody (AB154, domvanalimab) sponsored by Gilead Sciences was initiated for treatment of non-small cell lung cancer (NCT04736173).  The title of the study is "Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-10)."